Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancer.

The oncologist - 6 Aug 2026

Mohindroo Chirayu, Takahashi Nobuyuki, Nichols Samantha, Pinkiert Danielle, Thomas Anish

Abstract excerpt

BACKGROUND: Histologic transformation of EGFR-mutant non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is an aggressive resistance mechanism associated with poor outcomes and limited treatment options. Preclinical and clinical data suggest a rationale for combining PARP inhibition with immune checkpoint blockade in this setting. METHODS: We conducted an open-label, single-arm phase II study of...

Read the complete abstract on PubMed

Topics

Humans
Piperazines
Antibodies, Monoclonal
Female
Phthalazines
Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Lung Neoplasms

Aged

Middle Aged

Antineoplastic Combined Chemotherapy Protocols

ErbB Receptors

Small Cell Lung Carcinoma

Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 42605066
DOI: 10.1093/oncolo/oyag328
PMCID: PMC13544959

Genes

EGFR
RB1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancer.PMID 42605066Read ↗

Durable response to durvalumab-based immunochemotherapy in small-cell lung carcinoma transformation from EGFR-mutant non-small cell lung cancer: A case report.Semantic proximity Read ↗

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.Semantic proximity Read ↗

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic TargetsSemantic proximity Read ↗

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.Semantic proximity Read ↗

Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review.Semantic proximity Read ↗

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.Semantic proximity Read ↗

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.Semantic proximity Read ↗

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.Semantic proximity Read ↗

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: A retrospective and observational studySemantic proximity Read ↗

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.